BioSpace News Archive

The Parker Institute for Cancer Immunotherapy announced the appointment of Ute Dugan, MD, PhD, as Senior Vice President, Clinical Research.

The Cystic Fibrosis Foundation announced that it has awarded up to $2.17 million to Beyond Air® to support the development of a portable inhaled nitric oxide treatment for nontuberculous mycobacteria, difficult-to-treat bacteria that infect the lungs of people with cystic fibrosis.

InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine Manuscript Details Complete Six-Month INSPIRE 1.0 Primary Endpoint Study Results

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced it will be hosting a virtual Investor and Analyst Day on February 22, 2021 at 1:30pm PT / 4:30pm ET to discuss the company’s OPC1 program for acute spinal cord injury.

908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will participate in the following virtual investor conferences.

Mainstay Medical Holdings plc announced the closing of an equity financing in which it raised gross proceeds of US$108 million.

Helix BioPharma Corp. (TSX:HBP) , a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced the appointment of Dr. Frank Gary Renshaw to the Companys Scientific Advisory Board.

Halberd Corp. has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent pending Radio Frequency extracorporeal treatment to eliminate infectious disease pathogens.

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its fourth quarter and calendar year 2020 financial results on Monday, March 1, 2021 . The Company will also host a conference call beginning at 8:00 a.m. (EST) .

Pulse Biosciences Announces Start of Controlled Launch of the CellFX System ® - Shipments of First Commercial-Use CellFX Systems to U.S. and European Dermatologists Commence - First Aesthetic Dermatology Patients Treated in the U.S.